Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 186

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 186
---
, for example, by complying with prospectus requirements under the laws of that jurisdiction. There can be no assurance that NLS will take any action to register or otherwise qualify an offering of subscription rights or shares under the laws of any jurisdiction other than the United States where the offering of such rights is restricted. If shareholders in such jurisdictions were unable to exercise their subscription rights, their ownership interest in NLS will be diluted. NLS’s Common Shares are issued under the laws of Switzerland, which may not protect investors in a similar fashion afforded by incorporation in a U.S. state. NLS is organized under the laws of Switzerland. However, there can be no assurance that Swiss law will not change in the future or that it will serve to protect investors in a similar fashion afforded under corporate law principles in the United States, which could adversely affect the rights of investors. Risks Related to the Merger Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of NLS Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kadimastem. The Merger may be consummated on terms different than those contemplated by the Merger Agreement, or the Merger may not be consummated at all. If the Merger is not completed, or is completed on different terms from those contemplated by the Merger Agreement, NLS and Kadimastem could be adversely affected and subject to a variety of risks associated with the failure to consummate the Merger, or to consummate the Merger as contemplated by the Merger Agreement, including the following: •NLS’s shareholders and Kadimastem’s shareholders may be prevented from realizing the anticipated benefits of the Merger; •the market price of NLS Common Shares or Kadimastem Ordinary Shares could decline significantly; •reputational harm due to the adverse perception of any failure to successfully consummate the Merger; 59 •incurrence of substantial costs relating to the proposed Merger, such as legal, accounting, financial advisor, filing, printing and mailing fees, and, in certain cases, the payment by NLS of a termination fee to Kadimastem; and •the attention of NLS’s and Kadimastem’s management and employees may be diverted from their day -to-daybusiness and operational matters as a result of efforts relating to attempting to consummate the Merger. Any delay in the consummation of the Merger or any uncertainty about the consummation